| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print May 15, 2002
Department of Immunology, CSIC, Centro Investigaciones Biologicas, Madrid 28006
Corresponding Author: bernabeu.c{at}cib.csic.es
Endoglin is an auxiliary component of the transforming growth factor-
J. Biol. Chem, 10.1074/jbc.M111991200
Submitted on December 17, 2001
Revised on May 15, 2002
Accepted on May 15, 2002
Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-
receptors I and II
(TGF-) receptor system, able to associate with the signaling receptors types I (TRI) and II (TRII) in the presence of ligand, and to modulate the cellular responses to TGF-1. Endoglin cannot bind ligand on its own, but requires the presence of the signaling receptors, supporting a critical role for the interaction between endoglin and TRI or TRII. This study shows that full length endoglin interacts with both TRI and TRII, independently of their kinase activation state or the presence of exogenous TGF-1. Truncated constructs encoding either the extracellular or the cytoplasmic domains of endoglin, demonstrated that the interaction with the signaling receptors occurs through both extracellular and cytoplasmic domains. However, a more specific mapping revealed that the endoglin/TRI interaction was different from that of endoglin/TRII. TRII interacts with the amino acid region 437-558 of the extracellular domain of endoglin, whereas TRI interacts not only with the region 437-558, but also with the protein region located between amino acid 437 and the N-terminus. Both TRI and TRII interact with the cytoplasmic domain of endoglin, but TRI only interacts when the kinase domain is inactive, while TRII remains associated in its active and inactive forms. Upon association, TRI and TRII phosphorylate the endoglin cytoplasmic domain, and then TRI, but not TRII, kinase dissociates from the complex. Conversely, endoglin expression results in an altered phosphorylation state of TRII, TRI,and downstream Smad proteins, as well as a modulation of TGF- signaling, as measured by the reporter gene expression. These results suggest that by interacting through its extracellular and cytoplasmic domains with the signaling receptors, endoglin might affect TGF- responses.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Y. Lee, B. Ray, T. How, and G. C. Blobe Endoglin Promotes Transforming Growth Factor {beta}-mediated Smad 1/5/8 Signaling and Inhibits Endothelial Cell Migration through Its Association with GIPC J. Biol. Chem., November 21, 2008; 283(47): 32527 - 32533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. You, M. W. Bruinsma, T. How, J. H. Ostrander, and G. C. Blobe The type III TGF- receptor signals through both Smad3 and the p38 MAP kinase pathways to contribute to inhibition of cell proliferation Carcinogenesis, December 1, 2007; 28(12): 2491 - 2500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. English, E. A. Jones, D. Corscadden, K. Henshaw, T. Chapman, P. Emery, and D. McGonagle A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis Rheumatology, November 1, 2007; 46(11): 1676 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Y. Lee and G. C. Blobe The Interaction of Endoglin with beta-Arrestin2 Regulates Transforming Growth Factor-beta-mediated ERK Activation and Migration in Endothelial Cells J. Biol. Chem., July 20, 2007; 282(29): 21507 - 21517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Lopez-Novoa Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia Nephrol. Dial. Transplant., March 1, 2007; 22(3): 712 - 714. [Full Text] [PDF]
|
|
|
|
|
|
Q. Meng, A. Lux, A. Holloschi, J. Li, J. M. X. Hughes, T. Foerg, J. E. G. McCarthy, A. M. Heagerty, P. Kioschis, M. Hafner, et al. Identification of Tctex2beta, a Novel Dynein Light Chain Family Member That Interacts with Different Transforming Growth Factor-beta Receptors J. Biol. Chem., December 1, 2006; 281(48): 37069 - 37080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. I. Koleva, B. A. Conley, D. Romero, K. S. Riley, J. A. Marto, A. Lux, and C. P. H. Vary Endoglin Structure and Function: DETERMINANTS OF ENDOGLIN PHOSPHORYLATION BY TRANSFORMING GROWTH FACTOR-beta RECEPTORS J. Biol. Chem., September 1, 2006; 281(35): 25110 - 25123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bobik Transforming Growth Factor-{beta}s and Vascular Disorders Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1712 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Finnson, B. Y. Y. Tam, K. Liu, A. Marcoux, P. Lepage, S. Roy, A. A. Bizet, and A. Philip Identification of CD109 as part of the TGF-{beta} receptor system in human keratinocytes FASEB J, July 1, 2006; 20(9): 1525 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fernandez-L, F. Sanz-Rodriguez, F. J. Blanco, C. Bernabeu, and L. M. Botella Hereditary Hemorrhagic Telangiectasia, a Vascular Dysplasia Affecting the TGF-{beta} Signaling Pathway. Clin. Med. Res., March 1, 2006; 4(1): 66 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S A Abdalla and M Letarte Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease J. Med. Genet., February 1, 2006; 43(2): 97 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fernandez-L, F. Sanz-Rodriguez, R. Zarrabeitia, A. Perez-Molino, R. P. Hebbel, J. Nguyen, C. Bernabeu, and L.-M. Botella Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions Cardiovasc Res, November 1, 2005; 68(2): 235 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pece-Barbara, S. Vera, K. Kathirkamathamby, S. Liebner, G. M. Di Guglielmo, E. Dejana, J. L. Wrana, and M. Letarte Endoglin Null Endothelial Cells Proliferate Faster and Are More Responsive to Transforming Growth Factor {beta}1 with Higher Affinity Receptors and an Activated Alk1 Pathway J. Biol. Chem., July 29, 2005; 280(30): 27800 - 27808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tang, B. Low, S. A. Rutherford, and Q. Hao Thrombin induces endocytosis of endoglin and type-II TGF-{beta} receptor and down-regulation of TGF-{beta} signaling in endothelial cells Blood, March 1, 2005; 105(5): 1977 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lebrin, M. Deckers, P. Bertolino, and P. ten Dijke TGF-{beta} receptor function in the endothelium Cardiovasc Res, February 15, 2005; 65(3): 599 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Meurer, L. Tihaa, B. Lahme, A. M. Gressner, and R. Weiskirchen Identification of Endoglin in Rat Hepatic Stellate Cells: NEW INSIGHTS INTO TRANSFORMING GROWTH FACTOR {beta} RECEPTOR SIGNALING J. Biol. Chem., January 28, 2005; 280(4): 3078 - 3087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chen, J. L. Mehta, D. Li, L. Joseph, and J. Joseph Transforming Growth Factor {beta} Receptor Endoglin Is Expressed in Cardiac Fibroblasts and Modulates Profibrogenic Actions of Angiotensin II Circ. Res., December 10, 2004; 95(12): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Sadlier, S. B. Connolly, N. E. Kieran, S. Roxburgh, D. P. Brazil, L. Kairaitis, Y. Wang, D. C. H. Harris, P. Doran, and H. R. Brady Sequential Extracellular Matrix-focused and Baited-global Cluster Analysis of Serial Transcriptomic Profiles Identifies Candidate Modulators of Renal Tubulointerstitial Fibrosis in Murine Adriamycin-induced Nephropathy J. Biol. Chem., July 9, 2004; 279(28): 29670 - 29680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Conley, R. Koleva, J. D. Smith, D. Kacer, D. Zhang, C. Bernabeu, and C. P. H. Vary Endoglin Controls Cell Migration and Composition of Focal Adhesions: FUNCTION OF THE CYTOSOLIC DOMAIN J. Biol. Chem., June 25, 2004; 279(26): 27440 - 27449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. LEASK and D. J. ABRAHAM TGF-{beta} signaling and the fibrotic response FASEB J, May 1, 2004; 18(7): 816 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Berg, M Porteous, D Reinhardt, C Gallione, S Holloway, T Umasunthar, A Lux, W McKinnon, D Marchuk, and A Guttmacher Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations J. Med. Genet., August 1, 2003; 40(8): 585 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. DUFF, C. LI, J. M. GARLAND, and S. KUMAR CD105 is important for angiogenesis: evidence and potential applications FASEB J, June 1, 2003; 17(9): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Torsney, R. Charlton, A. G. Diamond, J. Burn, J. V. Soames, and H. M. Arthur Mouse Model for Hereditary Hemorrhagic Telangiectasia Has a Generalized Vascular Abnormality Circulation, April 1, 2003; 107(12): 1653 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mo, S. J. Fang, W. Chen, and G. C. Blobe Regulation of ALK-1 Signaling by the Nuclear Receptor LXRbeta J. Biol. Chem., December 20, 2002; 277(52): 50788 - 50794. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
